Dear UnitedHealth Stock Fans, Mark Your Calendars for July 16th

UnitedHealth Group (UNH) has long been one of the biggest names in the health insurance and managed care sector, wearing many hats with its insurance business and rapidly growing health arm. For years, it was the kind of stock investors would buy and let time do the heavy lifting. Then the tide turned. The past few years have thrown more than a few curveballs, with sharp increases in Medicare Advantage costs and rising pressures dragging stocks down. Although the stock has made an encouraging comeback in 2026, many investors are still waiting to see if this reversal has real legs.

That is why the 16th of July deserves a big circle in the calendar. UnitedHealth will report its second-quarter earnings before the market opens, and Wall Street will be watching closely for signs that the recovery is on track.

More news from Barchart

The company is headed for release with the wind behind it. In the first quarter, it beat Wall Street expectations, improved its medical care ratio to 83.9%, raised its full-year earnings guidance, and expressed confidence that its efforts to streamline operations and strengthen operations are starting to pay off.

With optimism building before the earnings release, let’s take a closer look at whether UNH stock still has room to run.

About UnitedHealth Stock

Founded in 1974 and based in Minnesota, UnitedHealth Group is one of the largest healthcare companies in the world, with a market capitalization of $386.3 billion. It operates through two complementary businesses: UnitedHealthcare, which provides health insurance to millions, and Optum, which provides technology-enabled care, pharmacy services, data analytics, and healthcare solutions. Together, they are creating an integrated healthcare ecosystem that integrates insurance and care delivery, helping to improve patient outcomes while driving long-term growth in the increasingly digital healthcare landscape.

UNH stock has endured more than its fair share of storms over the past year. After the 2025 injury, shares fell to a five-year low of $234.60 in August 2025 as investor sentiment took a hit and traders remained firmly in the driver’s seat. But all storms eventually run out of rain. Since hitting that bottom, the stock has bounced back about 81.6%, rebuilding lost ground.

That return helped push UNH to 38.3% over the past 52 weeks, with an impressive 28.9% gain already in 2026. Momentum has gathered speed recently, as the stock is up 53.4% ​​in the past three months and another 12.6% in the last month.

Technically, the image looks healthy. The 14-day RSI has settled at 64.87 after cooling from overbought levels in mid-May, while relatively muted trading volumes suggest investors are quietly accumulating shares rather than chasing a rally – a classic case of slowly winning the race!

In terms of pricing, UNH doesn’t exactly sound like a “bargain.” The stock trades at 22.60 times forward non-GAAP price, which is a premium to both industry peers and its historical average. If earnings continue to pile up, today’s multiples may prove too redundant in the long run. Meanwhile, its price-to-sales ratio of 0.85 times remains comfortably below both the sector median and its five-year average, suggesting the stock is underpriced from all angles.

And if there were any doubts about management’s confidence, their dividend policy tells a different story. Even after the stock’s poor performance earlier this year, UnitedHealth continues to reward shareholders. Earlier this month, the company raised its quarterly dividend by 5%, raising the payout from $2.21 to $2.32 per share. That marks its 16th consecutive year of dividend increases and extends its uninterrupted dividend payout streak to 24 years. And it brings the annual payout to $9.28 per share, offering a forward yield of about 2.21%, more than the SPDR S&P 500 ETF’s ( SPY ) yield of 1.01%.

A Closer Look at UnitedHealth’s Q1 Results

When UnitedHealth Group reported its first-quarter results on April 21, it gave investors reason to breathe a sigh of relief. The healthcare giant delivered a strong performance, with revenue up 2% year-over-year (YOY) to $111.7 billion, well beating Wall Street expectations. Adjusted earnings came in at $7.23 per share, up from a year earlier and reinforcing the view that the company is slowly getting back on track.

The quarter was flawless, but the good outweighed the bad. Growth in commercial fee-based memberships and other strong showings from Optum Rx helped power results, even as weakness at Optum Health and a decline in risk-based memberships acted as a drag. On the insurance side, premium income rose to $87.6 billion from $86.5 billion a year earlier.

Perhaps the most prominent area was medical expense management. UnitedHealth’s adjusted health care coverage ratio improved to 83.9%, down 90 basis points from last year, indicating that health care costs are under control. While medical expenses reached $73.5 billion, good inventory management and tight cost controls helped keep profits on track.

The balance sheet also went in the right direction. Cash and short-term investments increased to $31.2 billion, while long-term debt decreased to $71.4 billion. Meanwhile, operating cash flow rose to $8.9 billion from $5.5 billion a year earlier, giving the company enough cash to return $2 billion to shareholders in dividends per quarter.

Looking ahead, management was optimistic despite previously expecting 2026 revenue to top $439 billion, which would be slightly below 2025 levels due to positive operating sizing. The company raised its adjusted EPS outlook to more than $18.25, indicating an improvement in margins, while it previously projected margins of about 3.6%, $2.5 billion in share repurchases, $8 billion in dividends, and $3.8 billion in capital expenditures.

Even though medical memberships are expected to decline in several key segments, management believes that strong execution and disciplined cost control will keep the company moving in the right direction.

UnitedHealth is set to release its Q2 earnings report on Thursday, July 16, before the market opens. Analysts forecast revenue for the quarter to be around $111 billion and EPS to rise 18.6% YOY to $4.84. EPS for fiscal 2026 is expected to be $18.32, representing annual growth of 12.1%, and rise another 13.5% YOY to $20.80 in fiscal 2027.

What Are Analysts Expecting for UnitedHealth Stock?

Wall Street is growing more bullish on UnitedHealth ahead of its earnings report on July 16. Morgan Stanley recently raised its price target on UNH to $468 from $453 while reiterating its “Overweight” rating. The bank believes UnitedHealth is well-positioned to start the managed care earnings season on a strong note, supported by healthy healthcare spending and operational improvements at Optum Health.

It also expects the company to deliver second-quarter earnings per share above market estimates. In fact, Morgan Stanley named UnitedHealth one of its top picks, suggesting the strong report could set the stage for the entire managed care industry.

Analysts have grown more confident in the past few months. UNH had a “Neutral Buy” rating three months ago, but has now been upgraded to an overall “Strong Buy” rating. In fact, 19 of the 26 analysts covering UNH stock currently rate the stock a “Strong Buy.” Three analysts suggest a “Neutral Buy,” three play it safe with a “Hold,” and the remaining one analyst has “Strong Sell” ratings.

While the stock is hovering around an average price of $415, the Street-high target of $492 shows that UNH has a 15.7% upside to the last close.

At the date of publication, Sristi Suman Jayaswal did not have (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. This article was originally published Barchart.com